
Abstract Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) are classically associated with 4-repeat tauopathies, but emerging evidence indicates that a subset of patients with PSP-like or CBS-like phenotypes have autoimmune or paraneoplastic etiologies. These immune-mediated mimics can present with subacute onset, atypical features (such as prominent sleep disturbances, seizures, or rapid early progression), and the presence of specific neural autoantibodies. Recognizing these cases is critical, as they are potentially reversible with immunotherapy, unlike the relentlessly progressive course of neurodegenerative PSP/CBD. Here we review the mechanistic overlap between autoimmunity and neurodegeneration, highlight reported cases of autoimmune CBS and PSP mimics (and their characteristic clinical clues), and discuss immunotherapy strategies. While many patients improve with timely immunosuppressive treatment, outcomes vary by antibody type – reflecting direct pathogenic roles for cell-surface antibodies versus bystander phenomena in some intracellular (paraneoplastic) antibody cases. Ongoing research and accumulation of case reports will clarify the true frequency of autoimmune PSP/CBS and optimize their management
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
